Stock Events

Stock Events

NantKwest 

0
496
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 5Expected
Q1 2026
Q2 2026
Next
-0.53
-0.37
-0.22
-0.06
Expected EPS
-0.0623056
Actual EPS
N/A

Financials

-315.93%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
97.63MRevenue
-308.45MNet Income

Analyst Ratings

$10.37Average Price Target
The highest estimate is ⁦11.38⁩.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 26C.STU. It's not an investment recommendation.
NVIDIA
71
NVDA
Amazon
60
AMZN
Microsoft
59
MSFT
Alphabet
53
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap88.52B
Moderna is a leader in mRNA technology, directly competing in the development of vaccines and therapeutics, areas where ImmunityBio is also active.
BioNTech
BNTX
Mkt Cap22.15B
BioNTech, similar to Moderna, specializes in mRNA technology for developing vaccines, including for COVID-19, competing with ImmunityBio's efforts in vaccine development.
Novavax
NVAX
Mkt Cap1.66B
Novavax is a competitor in the vaccine space, particularly for COVID-19, where ImmunityBio also aims to make an impact.
Pfizer
PFE
Mkt Cap173.95B
Pfizer is a large pharmaceutical company with a broad portfolio that includes vaccines and cancer treatments, areas where ImmunityBio is also involved.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the development of vaccines and oncology treatments, overlapping with ImmunityBio's focus areas.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca is involved in developing vaccines and treatments for various diseases, including cancer, directly competing with ImmunityBio's research and development efforts.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences is a biopharmaceutical company that focuses on antiviral drugs and cancer therapies, competing with ImmunityBio in the oncology and infectious disease sectors.
AMGEN
AMGN
Mkt Cap251.94B
Amgen focuses on human therapeutics, including oncology and cardiovascular diseases, areas where ImmunityBio is also seeking to make advancements.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is known for its work in immunology and oncology, directly competing with ImmunityBio's efforts in developing immune-based therapies.
Novartis
NVS
Mkt Cap303.67B
Novartis is a global healthcare company that operates in various therapeutic areas, including oncology and vaccines, making it a competitor to ImmunityBio.

About

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Show More
CEO
Richard Gerald Adcock
Employees
691
Country
United States
ISIN
US63016Q1022
WKN
000A2QQ2E

Listings

XNAS
US
IBRX
XETRA
DE
26CA.XETRA
F
DE
26CA.F
MU
DE
26CA.MU

0 Comments

Share your thoughts

FAQs

What is NantKwest stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange NantKwest stocks are traded under the ticker 26C.STU.
When is the next NantKwest earnings date?▼
NantKwest is going to release the next earnings report on March 2, 2027.
What is NantKwest revenue for the last year?▼
NantKwest revenue for the last year amounts to 97.63M EUR.
What is NantKwest net income for the last year?▼
26C.STU net income for the last year is -308.45M EUR.
How many employees does NantKwest have?▼
As of November 7, 2026, the company has 691 employees.
In which sector is NantKwest located?▼
NantKwest operates in the Health & Wellness sector.
When did NantKwest complete a stock split?▼
NantKwest has not had any recent stock splits.
Where is NantKwest headquartered?▼
NantKwest is headquartered in SAN DIEGO, United States.